Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance

Table 1

Center	MGH	MGH	MGH	Stanford	Northwestern
Transplant type	HLA-matched related donor KdBMT for HM	Haploidentical donor KdBMT for HM	Haploidentical donor KdBMT for ESRD without malignancy	HLA-matched and haploidentical related and unrelated donor KdBMT for ESRD without malignancy	Haploidentical/mismatched related and unrelated donor KdBMT for ESRD without malignancy
Chimerism goal	FDC	FDC	Transient mixed	Sustained mixed	FDC
Results	Removal of IS in 5 of 10 patients (50%); Sustained antitumor responses in 30%	3 of 4 patients in remission, two likely tolerant	4 of 10 (40%) with sustained tolerance	Removal of IS in 44% (HLA-matched); 0% sustained tolerance (haploidentical or unrelated donor)	Removal of IS in 5 of 8 (63%) patients

KdBMT: kidney and bone marrow transplant; HM: hematologic malignancy; FDC: full donor chimerism; IS: immunosuppression.